Baxter Healthcare’s Auckland facility provides patients with over 200,000 units of chemotherapy, nutrition products and antibiotic therapies each year.
With their existing premises having been in operation since 1982, Baxter elected to construct a new dedicated pharmaceutical compounding facility to ensure it remained at the forefront of a highly competitive industry.
Johnstaff was engaged by Baxter to manage the design and construction of a new compounding facility, including specialist equipment installation, as well as the commissioning and validation of the building services and provision of IQ/OQ documentation for MedSafe accreditation.
The scope of this project required the detailed segregation of an existing sterile manufacturing facility and fully-functional receiving and distribution Warehouse to allow the construction of a new 1,100m² compounding facility located within the existing operational area.
Located within the heart of an existing operational facility, Johnstaff’s proactive and knowledgeable team and careful planning allowed the works to be executed without any breach to existing GMP conditions or loss of production time or manufacturing cycles.
The principles of “clean build” were adopted throughout the construction phase which facilitated and supported Baxter’s operational requirements for their manufacturing to be unaffected throughout the project.
1,100m² Grade B/C compounding facility which provides patients with over 200,000 units of chemotherapy, nutrition products and antibiotic therapies each year
No breach of GMP conditions or loss of production time or manufacturing cycles to the existing facility throughout the works
Awarded the 2016 AmCham (American Chamber of Commerce) DHL Express Success & Innovation Award.